Summit inks $58M development deal

Summit Corporation will pocket a $7 million upfront fee in the form of an equity investment from a new licensing pact with BioMarin Pharmaceutical. BioMarin inked a worldwide licensing agreement for Summit's preclinical candidate SMT C1100 and all follow-on molecules, which are being developed to treat the fatal genetic disorder Duchenne muscular dystrophy. Summit also stands to gain up to $51 million in milestones. Release

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.